(Q42557013)

2 November 2017

Study on didanosine concentrations in cerebrospinal fluid. Implications for the treatment and prevention of AIDS dementia complex (English)

1 reference

2 November 2017

0 references

1 reference

1 reference

7

J H Beijnen

1 reference

2 November 2017

D M Burger

1

1 reference

2 November 2017

C L Kraayeveld

2

1 reference

2 November 2017

P L Meenhorst

3

1 reference

2 November 2017

J W Mulder

4

1 reference

2 November 2017

R M Hoetelmans

5

1 reference

2 November 2017

C H Koks

6

1 reference

2 November 2017

language of work or name

English

0 references

publication date

1 November 1995

1 reference

International Journal of Clinical Pharmacy

2 November 2017

1 reference

2 November 2017

17

1 reference

2 November 2017

218-221

1 reference

2 November 2017

6

1 reference

Acquired immunodeficiency syndrome. Cerebrospinal fluid findings in patients before and during long-term oral zidovudine therapy

2 November 2017

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF01870615

Clinical pharmacology of 2',3'-dideoxyinosine in human immunodeficiency virus-infected children.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF01870615

Central nervous system targeting of 2',3'-dideoxyinosine via adenosine deaminase-activated 6-halo-dideoxypurine prodrugs

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF01870615

In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine

21 January 2018

1 reference

12 December 2020

Neuropathological evidence that zidovudine reduces incidence of HIV infection of brain

1 reference

12 December 2020

Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS Clinical Trials Group

1 reference

12 December 2020

Probenecid enhances central nervous system uptake of 2',3'-dideoxyinosine by inhibiting cerebrospinal fluid efflux.

1 reference

12 December 2020

Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection

1 reference

12 December 2020

Reduced frequency of HIV-induced brain lesions in AIDS patients treated with zidovudine.

1 reference

12 December 2020

AIDS dementia complex and didanosine

1 reference

12 December 2020

Pathogenesis and therapy of HIV-1 infection of the central nervous system.

1 reference

12 December 2020

Declining incidence of AIDS dementia complex after introduction of zidovudine treatment

1 reference

12 December 2020

Efflux of zidovudine and 2',3'-dideoxyinosine out of the cerebrospinal fluid when administered alone and in combination to Macaca nemestrina

1 reference

12 December 2020

Dideoxyinosine in Children with Symptomatic Human Immunodeficiency Virus Infection

1 reference

12 December 2020

Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection

1 reference

12 December 2020

Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex

1 reference

12 December 2020

Effects of zidovudine in 30 patients with mild to end-stage AIDS dementia complex.

1 reference

12 December 2020

Response of human-immunodeficiency-virus-associated neurological disease to 3'-azido-3'-deoxythymidine

1 reference

12 December 2020

Presentation and course of AIDS dementia complex: 10 years of follow-up in Amsterdam, The Netherlands.

1 reference

12 December 2020

Comparative pharmacokinetics of antiviral nucleoside analogues

1 reference

12 December 2020

Uptake kinetics of 2',3'-dideoxyinosine into brain and cerebrospinal fluid of rats: intravenous infusion studies.

1 reference

12 December 2020

Penetration of zidovudine into the cerebrospinal fluid of patients infected with HIV

1 reference

12 December 2020

Pharmacokinetics of 2',3'-dideoxyadenosine in dogs

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01870615

1 reference

2 November 2017

1 reference